Transparency Market Research in its new report titled, “Acquired Methemoglobinemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the acquired methemoglobinemia treatment market. The TMR report anticipates that the rise in incidence of acquired methemoglobinemia owing to increase in use of local anesthetics, surge in use of silver nitrates for the treatment of wounds, eating nitrate rich vegetables, and growing awareness about the available treatments will drive the acquired methemoglobinemia treatment market during the forecast period i.e, 2018-2026. High cost of blood products and lack of trained physicians in rural areas are the factors likely to restrain the global acquired methemoglobinemia treatment market, says the report.
The TMR report has segmented the global acquired methemoglobinemia treatment market based on type of treatment, end-user, and region. On the basis of type of treatment, the global market is categorized into drug therapy, blood transfusion therapy, and oxygen therapy. The drug therapy segment can be classified into methylene blue, dextrose, and ascorbic acid treatment. The methylene blue sub-segment is anticipated to dominate the drug therapy segment during the forecast period due to its positive performance to reverse the condition. In terms of end-user, the global acquired methemoglobinemia treatment market is divided into hospitals, clinics, and ambulatory care centers. The hospitals segment is expected to account for the major market share during the forecast period, attributed to patient preference for hospitals to treat such emergency cases and availability of equipment at hospitals such as oxygen therapy and blood transfusion devices. The clinics segment is expected to expand at the highest CAGR from 2018 to 2026.
On a geographical perspective, the global acquired methemoglobinemia treatment market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, according to TMR report, North America is expected to dominate the market due to availability of advanced therapeutic options to treat the disease, high health care awareness among the population, and high health care expenditure. The market in Asia Pacific is expected to expand at the highest CAGR due to increasing use of local anesthetics, rise in health care awareness, and surge in health care spending, as the report. High use of antibiotics such as dapsone and chloroquine to treat infections is responsible for rise in incidence of acquired methemoglobinemia in the region. Moreover, poor sanitation in Middle East & Africa, Latin America, and some parts of the Asia also contribute towards the increasing incidence of acquired methemoglobinemia in these regions. This is expected to further drive the growth of the global acquired methemoglobinemia treatment market during the forecast period.
Some of the major players operating in the global acquired methemoglobinemia treatment market are profiled in this report to give a better competitive analysis and these include GlaxoSmithKline plc, Mylan N.V., American Regent, Inc., Teligent, Inc., Provepharm Life Solutions, McGuff Company, Inc., Abundance Naturally Limited, Kedrion Biopharma, Inc., and Octapharma.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]